L’anticorps Lapin Polyclonal anti-BCL10 a été validé pour WB, IF, FACS, IHC (p) et EIA. Il convient pour détecter BCL10 dans des échantillons de Humain et Souris.
BCL10
Reactivité: Humain, Souris, Rat
WB, IHC, ELISA
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.25 mg/mL
Buffer
PBS containing 0.09 % (W/V) sodium azide as preservative
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Conseil sur la manipulation
Avoid repeated freezing and thawing.
Stock
4 °C/-20 °C
Stockage commentaire
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Antigène
BCL10
(B-Cell CLL/lymphoma 10 (BCL10))
Autre désignation
Bcl-10
Sujet
This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.Synonyms: B-cell CLL/lymphoma 10, BCL10, CARD-containing molecule enhancing NF-kappa-B, CARD-like apoptotic protein, CED-3/ICH-1 prodomain homologous E10-like regulator, CIPER, CLAP, Cellular homolog of vCARMEN, Cellular-E10, Mammalian CARD-containing adapter molecule E10, c-E10, cCARMEN, hCLAP, mE10